List of Xaciato drug patents

Xaciato is owned by Dare.

Xaciato contains Clindamycin Phosphate.

Xaciato has a total of 1 drug patent out of which 0 drug patents have expired.

Xaciato was authorised for market use on 07 December, 2021.

Xaciato is available in gel;vaginal dosage forms.

Xaciato can be used as method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation.

The generics of Xaciato are possible to be released after 22 September, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129896 DARE Topical formulations and treatments
Sep, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Dec 7, 2024
Generating Antibiotic Incentives Now (GAIN) Dec 7, 2029

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 07 December, 2021

Treatment: Method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation

Dosage: GEL;VAGINAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in